司来吉兰添加治疗帕金森病临床疗效评价

Clinical efficacy of selegiline added to levodopa/decarboxylase inhibitor in Parkinson's disease

目的 观察司来吉兰添加治疗帕金森病的临床疗效及安全性。方法 采用随机双盲安慰剂对照方法,在复方多巴治疗的基础上添加国产司来吉兰治疗40例帕金森病患者,分为司来吉兰治疗组和安慰剂对照组,疗程8周。采用改良的Webster评分量表评估药物疗效并观察不良反应。结果 司来吉兰治疗组治疗前后自身对照Webster评分有明显改善(P<0.05或P<0.01),安慰剂对照组于治疗后第4,6周差异有显著性意义(P<0.05或p<0.01),司来吉兰组疗效优于安慰剂组(P<0.01);司来吉兰组患者治疗的总有效率为80％,与安慰剂组(40％)比较差异有显著性意义(P<0.01)。司来吉兰组患者药物不良反应轻微。结论 司来吉兰是一种安全有效的抗帕金森病辅助药物。

Objective To investigate the efficacy and safety of selegiline added to Levodopa/decar-boxylase inhibitor in the treatment of patients with Parkinson' s disease. Methods The randomized, double-blind and placebo controlled study was performed. Selegiline was added to Levodopa/deearboxylase inhibitor in the treatment of 40 patients with Parkinson's disease for eight weeks. Efficacy of selegiline in each patient was evaluated by modified Webster rating scale. Tolerance and adverse effects were also observed. Results The significant improvement of parkinsonian symptoms was found in selegiline-added group and placebo group compared to Webster scale with pre- and post-treatmetnt (P<0.05 and P<0.01), but the effect in selegiline-added group was superior over the placebo group (P<0.01). The total effective rate was 80% and 40% in selegiline added group and placebo group respectively with significant difference (P<0.01). The adverse effects in treatment group were mild. Conclusion It is demonstrated that selegiline is a safe and effective supplementary drug for anti-Parkinson' s disease.